All new drugs* require prior approval until the D and T Advisory Board recommends that they be made available without prior approval. Even if a new drug is included in a PDL class, the D and T Advisory Board must approve the product as a new drug before it can be made preferred. Requests to be on the agenda must be submitted at least 3 weeks prior to the posted meeting date. If the request is not received at least 3 weeks prior to the meeting date, the drug will be added to the agenda of the subsequent meeting.
One appeal is allowed per year per product.
The drug must be available in the marketplace for 6 months before being reviewed by the D and T Advisory Board.
The D and T Advisory Board does NOT review non-drug products. Examples of these types of products include nutritional supplements, medical foods, medical devices, diagnostic tests, and supply items.
Products under review are posted at D and T Advisory Board